Investigational Drug Information for HSG4112
✉ Email this page to a colleague
What is the development status for investigational drug HSG4112?
HSG4112 is an investigational drug.
There have been 5 clinical trials for HSG4112.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 31st 2022.
The most common disease conditions in clinical trials are Overweight and [disabled in preview]. The leading clinical trial sponsors are Glaceum, Seoul National University Hospital, and Kyungpook National University Hospital.
Summary for HSG4112
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2022-01-31) |
| Vendors | 13 |
Recent Clinical Trials for HSG4112
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses | Seoul National University Hospital | Phase 1 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses | Glaceum | Phase 1 |
| A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients | Gangnam Severance Hospital | Phase 2 |
Clinical Trial Summary for HSG4112
Top disease conditions for HSG4112
Top clinical trial sponsors for HSG4112
US Patents for HSG4112
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
